GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Piotroski F-Score

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ARIAD Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for ARIAD Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


ARIAD Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for ARIAD Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Piotroski F-Score Chart

ARIAD Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 2.00 5.00 3.00

ARIAD Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 3.00 3.00 3.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep16) TTM:Last Year (Sep15) TTM:
Net Income was -59.871 + -53.787 + 109.848 + -27.827 = $-31.6 Mil.
Cash Flow from Operations was -38.587 + -65.095 + -32.652 + -23.689 = $-160.0 Mil.
Revenue was 36.504 + 35.597 + 68.125 + 46.016 = $186.2 Mil.
Gross Profit was 36.056 + 35.111 + 67.017 + 44.885 = $183.1 Mil.
Average Total Assets from the begining of this year (Sep15)
to the end of this year (Sep16) was
(576.139 + 546.692 + 502.549 + 624.367 + 676.591) / 5 = $585.2676 Mil.
Total Assets at the begining of this year (Sep15) was $576.1 Mil.
Long-Term Debt & Capital Lease Obligation was $522.9 Mil.
Total Current Assets was $351.2 Mil.
Total Current Liabilities was $110.8 Mil.
Net Income was -5.751 + -52.676 + -63.16 + -55.451 = $-177.0 Mil.

Revenue was 66.835 + 23.991 + 29.238 + 29.07 = $149.1 Mil.
Gross Profit was 65.888 + 23.296 + 28.75 + 28.587 = $146.5 Mil.
Average Total Assets from the begining of last year (Sep14)
to the end of last year (Sep15) was
(483.692 + 603.116 + 580.451 + 542.977 + 576.139) / 5 = $557.275 Mil.
Total Assets at the begining of last year (Sep14) was $483.7 Mil.
Long-Term Debt & Capital Lease Obligation was $419.7 Mil.
Total Current Assets was $329.5 Mil.
Total Current Liabilities was $115.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ARIAD Pharmaceuticals's current Net Income (TTM) was -31.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ARIAD Pharmaceuticals's current Cash Flow from Operations (TTM) was -160.0. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep15)
=-31.637/576.139
=-0.0549121

ROA (Last Year)=Net Income/Total Assets (Sep14)
=-177.038/483.692
=-0.36601391

ARIAD Pharmaceuticals's return on assets of this year was -0.0549121. ARIAD Pharmaceuticals's return on assets of last year was -0.36601391. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ARIAD Pharmaceuticals's current Net Income (TTM) was -31.6. ARIAD Pharmaceuticals's current Cash Flow from Operations (TTM) was -160.0. ==> -160.0 <= -31.6 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep15 to Sep16
=522.905/585.2676
=0.89344601

Gearing (Last Year: Sep15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep14 to Sep15
=419.722/557.275
=0.75316854

ARIAD Pharmaceuticals's gearing of this year was 0.89344601. ARIAD Pharmaceuticals's gearing of last year was 0.75316854. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep16)=Total Current Assets/Total Current Liabilities
=351.239/110.843
=3.16879731

Current Ratio (Last Year: Sep15)=Total Current Assets/Total Current Liabilities
=329.535/115.676
=2.84877589

ARIAD Pharmaceuticals's current ratio of this year was 3.16879731. ARIAD Pharmaceuticals's current ratio of last year was 2.84877589. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ARIAD Pharmaceuticals's number of shares in issue this year was 193.225. ARIAD Pharmaceuticals's number of shares in issue last year was 188.921. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=183.069/186.242
=0.98296303

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=146.521/149.134
=0.98247884

ARIAD Pharmaceuticals's gross margin of this year was 0.98296303. ARIAD Pharmaceuticals's gross margin of last year was 0.98247884. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep15)
=186.242/576.139
=0.3232588

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep14)
=149.134/483.692
=0.30832431

ARIAD Pharmaceuticals's asset turnover of this year was 0.3232588. ARIAD Pharmaceuticals's asset turnover of last year was 0.30832431. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ARIAD Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

ARIAD Pharmaceuticals  (NAS:ARIA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ARIAD Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan officer: Sr. V. P. - General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni officer: EVP, CFO & Treasurer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson officer: President, R&D, CSO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag officer: Sr. VP, Reg. Affairs & Quality C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole officer: SVP, Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos director, officer: President and CEO ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli director C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall officer: EVP, CCO MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska officer: SVP, Clinical R&D, CMO C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus